MFADX
Price
$25.91
Change
+$0.07 (+0.27%)
Updated
Oct 8 closing price
Net Assets
90.15M
REMIX
Price
$14.53
Change
+$0.12 (+0.83%)
Updated
Oct 8 closing price
Net Assets
740.11M
Interact to see
Advertisement

MFADX vs REMIX

Header iconMFADX vs REMIX Comparison
Open Charts MFADX vs REMIXBanner chart's image
Cromwell Long Short Investor
Price$25.91
Change+$0.07 (+0.27%)
VolumeN/A
Net Assets90.15M
Standpoint Multi-Asset Investor
Price$14.53
Change+$0.12 (+0.83%)
VolumeN/A
Net Assets740.11M
MFADX vs REMIX Comparison Chart in %
View a ticker or compare two or three
VS
MFADX vs. REMIX commentary
Oct 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MFADX is a StrongBuy and REMIX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
REMIX has more cash in the bank: 740M vs. MFADX (90.2M). REMIX pays higher dividends than MFADX: REMIX (5.52) vs MFADX (0.83). MFADX was incepted earlier than REMIX: MFADX (13 years) vs REMIX (6 years). MFADX (2.34) is less costly to investors than REMIX (1.64). MFADX has a lower initial minimum investment than REMIX: MFADX (2000) vs REMIX (2500). MFADX annual gain was more profitable for investors over the last year : 14.34 vs. REMIX (1.87). REMIX return over 5 years is better than : 52.17 vs. MFADX (42.33).
MFADXREMIXMFADX / REMIX
Total Expense Ratio2.161.51143%
Annual Report Gross Expense Ratio2.341.64143%
Fund Existence13 years6 years-
Gain YTD14.4381.0521,373%
Front LoadN/AN/A-
Min. Initial Investment2000250080%
Min. Initial Investment IRAN/AN/A-
Net Assets90.2M740M12%
Annual Yield % from dividends0.835.5215%
Returns for 1 year14.341.87767%
Returns for 3 years28.1614.15199%
Returns for 5 years42.3352.1781%
Returns for 10 years78.54N/A-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HLLY3.080.13
+4.41%
Holley
SER5.630.23
+4.26%
Serina Therapeutics
BIO302.836.31
+2.13%
Bio-Rad Laboratories IncClass A
NVCR14.350.19
+1.34%
NovoCure Limited
EURKU10.89N/A
N/A
Eureka Acquisition Corp.